The threat of a government shutdown sent the markets tumbling to close lower with the Dow dropping 87 points to 21,812. Nasdaq fell 19 points to 6,278.
On the upside
Express (NYSE: EXPR) reported a smaller than expected loss for the second quarter.
Paratek Pharmaceuticals (Nasdaq: PRTK) will present at five upcoming investor conferences.
The Food and Drug Administration has completed its review of Intra-Cellular Therapies' (Nasdaq: ITCI) responses to the regulatory agency's requests for additional information and will allow the biopharmaceutical to proceed with its long term safety study of lumateperone.
On the downside
La-Z-Boy (NYSE: LZB) disappointed with lower first quarter earnings that fell short of expectations.
Ultragenyx Pharmaceutical (Nasdaq: RARE) will discontinue clinical development of Ace-ER after disappointing Phase 3 study results.
Apogee Enterprises (Nasdaq: APOG) trimmed its fiscal 2018 revenue outlook.
In the broad market, advancing issues outpaced decliners by a margin of 9 to 8 on the NYSE while decliners edged out advancers by nearly 6 to 5 on Nasdaq. The broader S&P 500 fell 8 points to 2,444. Bitcoin added $9 to $4,092.
